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Abstract
Rheumatoid arthritis (RA) is a progressive autoimmune inflammatory disorder 
characterized by cellular infiltration in synovium causing joint destruction and 
bone erosion. The heterogeneous nature of the disease manifests in different clinical 
forms, hence treatment of RA still remains obscure. Treatments are limited owing 
to systemic toxicity by dose-escalation and lack of selectivity. To overcome these 
limitations, Smart drug delivery systems (SDDS) are under investigation to exploit 
the arthritic microenvironment either by passive targeting or active targeting to 
the inflamed joints via folate receptor, CD44, angiogenesis, integrins. This review 
comprehensively deliberates upon understanding the pathophysiology of RA and 
role of SDDSs, highlighting the emerging trends for RA nanotherapeutics.
Keywords: smart drug delivery systems, active & passive targeting, Stimuli-
responsive nanoparticles, polymer-drug conjugates, Arthritic microenvironment
1. Introduction
Rheumatoid arthritis (RA) is an autoimmune-mediated systemic, chronic 
inflammatory disorder characterized by progressive inflammation of joints, cell 
infiltration, pannus formation, synovial dysplasia resulting in cartilage destruction 
and bone erosion [1]. The worldwide prevalence rate of RA in adult population has 
been predicted between 0.5–1% and 0.92% in India [2]. Generally, prevalent in 
women when compared to men (3,1) at any age group. According to recent statistics 
given in 2019 by the Global RA network and WHO, 23 million people are affected 
by RA, globally [3]. RA etiology is implicated to be linked to metabolic, genetic, 
environmental factors, and life style of the patient [4]. While it is considered 
non-lethal, RA is debilitating and severely compromises the quality of life, further 
reducing life expectancy in patients.
Despite tremendous progress in evolving efficient pharmacological molecules 
for RA therapy, their efficacious delivery at the diseased joint remains a long-lasting 
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challenge. Over the last two decades, disease-modifying anti-rheumatic drugs 
(DMARDs: such as methotrexate (MTX), hydroxychloroquine (HCQ ), sulfasala-
zine (SSZ), leflunomide (LFM), have attracted attention for effective attenuation 
of disease progression. Patient compliance is the primary treatment goal with 
glucocorticoids(GCs); e.g., prednisolone, dexamethasone, hydrocortisone, triam-
cinolone acetonide, and NASAID (such as ibuprofen, diclofenac, indomethacin 
etc) result in reducing pain and curbing disease progression [5]. Unfortunately, 
the associated toxicity caused by dose-escalation and long-term use with undesir-
able side-effects are limiting the therapeutic success. Continued medication of 
NSAIDs causes gastro-intestinal and renal toxicity; glucocorticoids cause hyper-
tension, hyperglycemia, muscle wasting, osteoporosis, etc.; nausea and vomiting 
are common side-effects of conventional DMARDs, including gastro-intestinal 
irritations, headaches, insomnia, cytopenia, skin and hair damage, etc.; giving 
biologicals run the risk of anaphylaxis, infections, malignancy, psoriasis and other 
autoimmune disorders [6, 7]. Biosimilars/biologicals/Biological response modifiers 
like infliximab, adalimumab, rituximab etc. that have approval of Food and Drug 
Administration (FDA), were considered for their selective site-specific action, 
achieved extensive success in clinics for RA treatment. Prior reports suggest com-
bination therapy with biologics, and synthetic DMARDs were found to be highly 
effective [8].
To circumvent the off-target drug induced systemic toxicity, direct drug delivery 
via the intra-articular injection to the affected joints was explored. Nevertheless, 
this mode of administration has several limitations, as it necessitates repeat injec-
tions in the joint, risk of infection, and joint disability. Therefore, a concerted effort 
for development of novel therapies are clearly warranted with a focus on targeting 
the inflamed joints.
Nanotherapeutics has emerged as an innovative approach enabling efficient 
delivery of drug for mitigating several diseases. The past decade, has seen an 
avalanche of publications that have increased our understanding of the patho-
physiology of the affected synovial tissue in RA and equivalent progress in nano-
technology and material chemistry, generating tremendous interest in developing 
Smart drug delivery system (SDDS). Entrapping the anti-inflammatory drugs in 
SDDS strategically has potential to overcome all the barriers of normal delivery, 
projecting it as a promising option for site-specific delivery. Currently, RA targeting 
nanotherapeutics has progressed rapidly because the inflammatory microenviron-
ments of arthritic joints mimic the tumor environment that has typical angiogenic 
features of neo-vessels coupled with impaired peripheral lymphatic drainage 
[9, 10]. This review comprehensively deliberates upon the understanding the 
pathophysiology of RA and role of SDDSs, highlighting the emerging trends for RA 
nanotherapeutics.
2. RA microenvironment
Chronic inflammation is the hallmark of RA that advances to destructive synovi-
tis [11]. It develops in a genetically susceptible person largely due to environmental 
factors and related epigenetic mechanisms [12]. It predominantly indicates leuko-
cyte infiltration, dysregulated angiogenesis, proliferation of lining layer, that alters 
the synovial tissue into an invasive pannus. The microvasculature of synovium is 
dysregulated, hence, in spite of enhanced flow of blood, the increased metabolic 
needs outdo the vascular blood supply, thereby creating an intense hypoxic micro-
environment. However, rheumatoid factor (RF) and anticitrullinated peptide 
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antibodies(ACPA) are induced and must exist before the onset of this disease. The 
heterogeneous nature of the disease manifests in different clinical forms, hence 
treatment of RA still remains obscure. It is well documented that synovial micro-
environment has abundance of macrophages, multifaceted crosslink of immune 
cells secreting granulocyte colony-stimulating factor, pro-inflammatory cytokines, 
tumor necrosis factor(TNF-α), interleukin (IL-1), IL-6, chemokines, and degrading 
like MMPs that are particularly responsible for RA pathogenesis [13, 14]. Figure 1 
illustrates the network of cytokines secreted by multitude of cells involved in RA 
development that can be useful for assessment of disease progression along with 
biomarkers present on these cells.
2.1 Synovial fibroblasts (SF)
Proliferation and infiltration of SF is the key trigger for disease progression in 
RA. Under normal conditions fibroblasts are responsible for maintaining tissue 
homeostasis by modulating the inflammatory response [15]. Transcription factors 
like activator protein-1 and NF-κB, responsible for proliferation, activation, dif-
ferentiation of fibroblasts, expression of MMPs, other matrix-degrading enzymes 
like cysteine proteases and aggrecanases have been observed in the synovium [5]. 
The genetic analysis of synovium would be useful for biological therapy as synovial 
tissue has a robust immune-inflammatory gene expression [16].
2.2 B cells
B cells contribute to antibody production i.e. RF and anticyclic citrullinated 
peptide antibody (ACPA), and other effector roles to entail disease progression 
[17]. RF and/or ACPA promotes severe bone and joint erosions as the citrullinated 
proteins aggravate RA progression [18]. B cells are pointedly responsible for regula-
tion of inflammatory response by serving as antigen-presenting cells and releasing 
Figure 1. 
Schematic illustration indicating the key events and signaling cascades involved in RA pathophysiology. 
Leukocytes infiltrate synovium and stimulate the inflammatory cascade, characterized by cross-talk of SF 
and macrophages, monocytes, mast cells, dendritic cells, as well as B and T cells. Endothelial cells facilitate 
angiogenesis. The advanced stage includes hyperplastic synovium, cartilage damage, bone erosion, and systemic 
consequence. Bone resorption by osteoclasts practically creates bone erosions. The obliteration of the subchondral 
bone can ultimately lead to the degeneration of the articular cartilage that is a result of reduced osteoblasts and 
an increase in the number of osteoclasts and synoviocytes.
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pro−/anti-inflammatory cytokines that additionally control T cell differentiation 
and proliferation, and activation of macrophages [5].
2.3 T cells
Activated T cells comprise ≥50% of RA synovial cells, and majority are memory 
CD4 T cells. In terms of T cell subsets, the Th1(T helper 1) and Th17(T regulatory) 
are predominant, but lack Th2 subsets [5]. T cells release cytokines as their effector 
functions; Th1 release interferon gamma(IFN-γ), that further activate macrophages 
and increases its phagocytic activity. Likewise, effector cytokines of Th17 cells are 
IL-17A, IL-17F, IL-21, and IL-22, responsible for cell recruitment, secretion of pro-
inflammatory cytokines, initiation of differentiation of B-cell, and activate NK cells 
[19]. IL-17 may emerge as a beneficial target for RA therapies.
2.4 Macrophages
Macrophages are tightly regulated by microenvironment signals including 
presence of injured cells, microbial debris, pro/anti-inflammatory cytokine or 
mechanical forces [19]. Depending on the cues, macrophages tend to polarize 
into characterized phenotypes like pro-inflammatory or immunomodulatory 
[20]. Taking advantage of the fundamental homing capability of macrophages 
to migrate to the injured/inflamed arthritic synovium, macrophages can be 
exploited as delivery vehicles to target specific macrophage populations to carry 
payloads.
2.5 Osteoclasts
Enhanced osteoclast activity triggered by disproportionate ratio of 
Osteoprotegerin (OPG) and receptor activator of nuclear-factor kappa-beta ligand 
(RANKL) are critical factors for RA progression. When RANKL is overexpressed 
by activated macrophages, osteoblasts and lymphocytes, it stimulates an imbal-
ance between osteoclast multiplication and anomalous activation triggered by the 
binding of RANKL to RANK on the mature osteoclasts and on the cell-membranes 
of precursor cells of osteoclast [21]. In addition, MMP-9 and MMP-14 secreted by 
the osteoblasts, triggers matrix degradation in cartilage, formation of pannus, and 
osteoclast migration to surface of the bone. Osteoclasts significantly cause erosion 
of subchondral bone, articular cartilage, and the synovium.
2.6 Enzymes & other effector molecules
MMPs are the enzymes that irreversibly cause extracellular matrix (ECM) 
degradation, and slow-destruction of cartilage and bone in diseased joints. MMPs 
are zinc-dependent endopeptidases that are categorized into five sub-classes: i) 
gelatinases (MMP-2 and 9), ii) collagenases (MMP-1, −8 and 13), iii) stromelysins 
(MMP-3, −10 and − 11), iv) matrilysins (MMP-7 and -26) and v) membrane-type 
MMPs (MMP-14 to −17, −24 and − 25) [22, 23]. MMP-1, 2, 3, and 9 have been 
directly implicated in RA progression [24]. MMPs, in combination with lipases 
and esterases, accelerate degradation of ECM, articular cartilage and surface of 
the subchondral bone [25]. Ever-increasing emerging targets including these 
enzymes provide more options for anti-arthritic therapy with the help of targeted 
SDDS for RA.
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3. Rationale of SDDS
Enhancement of therapeutic efficiency by ‘intelligent/smart’ carriers that 
release drugs in a controlled manner at the site of action to achieve minimal side 
effects are categorized as “Smart Drug delivery system” (SDDS). Maintaining 
optimum size and surface properties, the materials can be engineered to create 
nanoparticles that can maneuver the microenvironment and respond to endogenous 
stimuli, like increased concentration of some enzymes, redox gradient-enhanced 
level of glutathione, or variations in interstitial pH [26] and/ or exogenous stimuli 
that include temperature changes, applying magnetic field or light, and giving high 
energy radiation.
3.1 pH-responsive
pH, an important parameter linked to pathophysiological conditions, like 
inflammation can be exploited for enhanced therapeutic efficiency [27]. Reports 
priori give clarity that pH in normal tissue and blood is maintained around 7.4, 
but in arthritic microenvironment, extracellular pH values are intrinsically acidic, 
usually pH 6.8 [28]. The acidic pH can be attributed to the excess infiltration and 
activation of proinflammatory cells in the synovium, causing increased demand 
for oxygen and energy. Augmented consumption of glucose via glycolysis con-
sequently enhances production of lactic acid, that causes local acidosis [29, 30]. 
Hence, the nanoparticles should be strategically designed to sensitively distinguish 
pH changes in inflammatory area where high disease activity and joint destruction 
correlates with low synovial pH. These pH-responsive nanoparticles encapsulat-
ing therapeutic molecules like NSAIDs, DMARDs etc. can be promising for RA 
treatment. Even at the cellular level, pH-sensitive SDDS can either stimulate drug 
release into lysosomes, or the late endosomes or may even trigger the escape of 
nanoparticles from lysosomes into the cytosol [31]. Appropriate size will enable 
efficient penetration in the inflamed joints, facilitated by angiogenesis during RA 
progression, that causes endothelial cell discontinuity leading to enhanced vascular 
permeability [32].
Two strategies are rationally used to design of pH-sensitive SDDS, one using 
materials with acid-sensitive bonds, that can be cleaved by low pH conditions 
allowing the release of encapsulated molecules from the nanoparticles; and sec-
ondly, using polymers (polyacids or polybases) that have ionizable groups, that 
undergo pH-dependent transformation and change in solubility [33]. Researchers 
have engineered a dual-strategy by attributing targeting abilities by surface func-
tionalization and simultaneously using pH responsiveness to enhance therapeutic 
selectivity in RA.
3.2 Redox-responsive
Intracellular microenvironment can be exploited using redox responsive 
NPs. Reactive oxygen species (ROS) is generated primarily during oxidative 
phosphorylation(OXPHOS), but can further be produced by oxidative burst of 
activated phagocytic cells [34]. Polymers with ROS-sensitive thioketal moiety, 
or selenium (Se), tellurium (Te), B-based linkers in their monomeric back-
bone can be utilized as building blocks for the synthesis of stimuli- responsive 
nanoparticles. Hence, ROS can easily be monitored as an intracellular indica-
tor [35] as chronic inflammation induces continuous production of ROS [36]. 
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ROS concentrations in inflammatory tissues ranges 10- to 100- fold higher than 
normal tissues [36], thus, promising accuracy and specificity to develop the redox 
stimuli-responsive DDSs.
3.3 Temperature-responsive
Temperature is another crucial factor essential for release of drug [38], as 
the normal physiological conditions have lower temperatures compared to the 
inflamed RA microenvironment [39]. Therefore temperature-responsive function-
alized NPs can be used to trigger the release of drug at the inflammatory site. They 
are designed and fabricated to retain their payloads at physiological temperature 
(37°C), and quick release it when the temperature is increased around 40–45°C, 
attributing a more efficient targeted SDDS [40]. Phase-transition behavior of 
the materials that are thermosensitive are used to design NPs, based on the lower 
critical solution temperature (LCST) of polymers/lipids whose solubility varies 
with changes in temperature. All excipients in a mixture are totally miscible in all 
amounts in LCST. In materials with transitional behavior, increased solubility is 
observed below LCST; and polymeric constituents are prone to swelling due to 
the hydrogen bonds being formed between the polymer functional groups with 
water molecules enabling drug loaded molecules. When temperature is raised 
above the LCST, a hydrophobic-hydrophilic conversion takes place, that leads to 
a morphological transformation from a random coil-to-globular form. Because 
of alterations in temperature, the hydrogen bonds breaks causing the network to 
collapse, and the polymer becomes insoluble, causing shrinkage in the volume 
and oozing-out of water molecules from inside. This transition initiates release 
of the entrapped payload of drugs. The application of thermo-responsive SDDS 
is based on the concept of exploiting the temperature difference between healthy 
and diseased tissues [40]. Thermal energy can be given directly, or external 
utilizing heat sources like NIR that may be indirectly applied in RA, that elicits a 
thermo-responsive behavior based on the thermo-sensitivity of nanomaterials. 
Typically, the requisite range of temperature fluctuates from 38–43°C [37]. The 
temperature-stimuli can originate from within the body, or by localized hypo-
thermia, or hyperthermia, may provoke a response based entirely on the thermo-
sensitivity of used nanomaterials. Additional advantages of thermo-sensitive NPs 
may be attributed to reduction in use of toxic organic solvents during fabrication, 
the capacity to entrap both lipophilic and hydrophilic molecules, controlled and 
sustained release properties. A plethora of reports using several polymers have 
been established for the synthesis of temperature-responsive systems, that include 
derivatives of poly(N-isopropylacrylamide (PNIPAAm), pluronics (poly(ethylene 
oxide)- poly(propylene oxide) (PEO-PPO)), poly(N vinyl caprolactam), polysac-
charide spinoffs, and derivatives of phosphazene [41–43]. Researchers are making 
concerted efforts on achieving temperature-responsive NPs stimulated by mag-
netic action coupled with thermo-responsive effect by light absorption instead of 
temperature alone.
3.4 Light and magnetic responsive
Light-responsive systems rely on an external stimulus to activate the drug 
release preferably at the target site using light irradiation. NPs respond to ‘on–off 
drug’ release, as it may close/open when stimulated using light radiation. Also 
termed as photodynamic therapy, SDDS based on magnetic stimuli represents 
another external way to trigger drug release at the target site under programmable 
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exposure of magnetic field [37]. Iron-oxide NPs have excellent potential for smart 
drug delivery, as it exhibits a significant response to both light and magnetic stim-
uli, it can be exploited for triggering a burst release of drug at the inflamed sites 
of RA termed as the magneto-calorific effect and photothermal effects. Thermal 
properties of magnetic NPs might be conveniently modulated by modifying their 
own viscosity in the endo-cellular environment. Photodynamic therapy (PDT) 
and photothermal therapy (PTT) use photosensitizers as therapeutic molecules. 
Moreover, near infrared(NIR) light can efficiently infiltrate the inflamed RA joints. 
Cu7.2S4 nanoparticles triggered with NIR irradiation (808 nm, 1 W cm
−2) was sug-
gested to accomplish improved bone mineral density (BMD) and bone structure 
and volume. It further impedes invasion to synovial tissue, erosion of cartilage and 
bone in vivo.
Huo et al. have prepared optical nanoparticles induced PTT and PDT and docu-
mented probable pathways for cell toxicity [44]. During PTT cell necrosis can be 
induced by NIR laser light irradiation (wavelength:1064 nm), however when given 
as combination therapies (PTT + PDT), evidence of both necrosis and apoptosis 
pathways are indicated. Furthermore, PTT-PDT combination given simultaneously, 
can account for immunogenic cell-death, while fluorophores can be used for optical 
imaging as a diagnostic tool that can be applied for RA too.
3.5 Enzyme responsive
Specific enzymes like phospholipases, proteases, or glycoside are often over-
expressed in different pathological conditions, like inflammation, and can be 
exploited for enzyme triggered release and accumulation of drugs at the targeted 
site of interest [37]. Nevertheless, nature of cleavable units, the sensitivity of the 
delivery system can significantly influence the pharmacokinetics of entrapped 
payload. Further, it must be ensured that the metabolites or the degraded moi-
eties are non-toxic and biocompatible and are cautiously eliminated from the 
body. Therefore, in future, enzyme-responsive nanoparticles offer tailor-made 
therapy according to variations in levels of disease expression. Redox- and 
enzyme-responsive nanoparticles are coming up as promising therapies in RA 
treatment.
3.6 Energy upconversion NPs
Nanomaterials with exceptional physico-chemical properties targeting the 
lesions can be supplemented with precise external stimuli, such as light, microwave, 
ultrasound, and radiation. Upconversion nanoparticles (UCNPs) synthesized 
from rare-earth elements that are capable of translating NIR photons that have 
low-energy to high-energy ultraviolet or visible photons [45]. These extraordinary 
NIR excitation based optical properties of UCNPs allows penetration to deep 
tissues with minimum auto-fluorescence background, reinforcing a wide array of 
diagnostic applications alongwith biomedical imaging system [46, 47]. SDDS can 
translate the external stimuli and equivalent energy input into beneficial effects or 
release the payload via an energy-upconversion process [48]. Ultrasound-based, 
photo-dynamic-based, radiation-based and microwave-based, energy-UPNPs have 
been widely explored in RA treatment as an alternative therapy (Figure 2). These 
developing technologies induce death of synovial fibroblasts and other inflamma-
tory cells by generating hyperthermia, cellular ROS, mechanical and photoelectric 
effects [49]. Synovial cells can be directly targeted by nanoparticles to decrease 





Stimulus Description of the system Drug References
Chemical pH PLGA-PK3-lipid-polymer hybrid 
nanoparticles decorated with stearic 
acid-octa-arginine and folic acid (Sta-R8-FA-
PPLPNs/MTX) [PK3, Folate-PEG-PLGA, egg 
PC, and Sta-R8]
MTX [51]
pH Polymeric nanoparticles surface modified 
with Hyaluronic acid (HA)- (HAPNPs) 
consisting of polyethylenimine, egg 
phosphatidyl-choline, and PCADK
Dex [52]
pH PEGylated hyaluronic acid(P-HA) 
mineralized nanoparticles having a 
hydrophilic shell, 5β-cholanic acid as 
the hydrophobic core and CaP as the 
pH-responsive mineral
MTX [53]
pH Lipid nanocarriers formed by PEG-PLGA 
hydrophilic shell, functionalized with folic 
acid (FA) ligand for targeting FA-receptor, 
poly (cyclohexane-1,4-diylacetone 
dimethylene ketal) (PCADK) & PLGA as 
the hydrophobic core. PCADK was used as 
pH-responsive material
MTX [54]
pH Spherical self-assembled micelles of poly 
(β-amino ester)-graft-poly(ethylene glycol) 
(PAE-g-PEG) encapsulating MTX into the 
hydrophobic core.
MTX [55]
pH Acetone-ketal-linked pro-drugs (AKP-dexs) 
pH-sensitive of dexamethasone nanoparticles
Dex [56]
ROS Folate conjugated to PEC 100 monostearate 
as film-forming material, and methotrexate 
(MTX) and catalase (CAT) co-encapsulated 
liposomes (FOL-MTX&CAT-L)
MTX [57]
Physical NIR Gold half-shell nanoparticles functionalized 
with RGD to target the inflammation, 
encapsulating methotrexate (MTX).
MTX [58]
PDT/PTT Copper (Cu)-based nanomaterials with 
assistance of L-cystein termed as Cu7.2S4 
nanoparticles (NPs)
__ [59]
Magnetic Magnetic iron oxide nanoparticles (IONPs) __ [60]
Multimodal 
Imaging
Light Nanoparticles composed of PLGA 





Lipid nanoparticles with PEG coating, 






Cytokines Nanoparticle system based on two natural 
polymers-N-trimethyl chitosan (TMC) 





Temp & pH MTX loaded Gold nanoparticles and 
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4. Principle of SDDS
Presently, the conventional treatments exhibit escalation in dose and systemic 
toxicity upon administration of drug. Most anti-inflammatory therapeutic drugs 
are equitoxic to both the normal cells and inflamed cells. SDDS has been well 
recognized in the past few decades owing to its potential for site-specific and tar-
geted delivery [66] Encapsulation of anti-inflammatory drugs in nanoparticles 
can enhance the site-specificity, reduce the dose, curtail the systemic toxicity 
and improve the biodistribution to targeted disease site [67]. To overcome the 
disadvantage of conventional delivery of drugs, selective delivery whether pas-
sive or active can be used for targeting drug to the site of action as SDDS in RA 
therapy.
Figure 2. 
Schematic representation of stimuli-responsive polymers for nanotherapeutics of rheumatoid arthritis (RA).
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Passive targeting can be accomplished by targeting the physiological and anatomi-
cal changes in inflamed tissues, that occurred due to RA. For passive targeting, NPs do 
not require any surface modification, either by conjugation or by attaching a surface 
ligand. Various studies have shown the enhanced permeability and retention (EPR) 
mechanism for passive accumulation in inflamed tissues [68]. In the inflammatory RA 
milieu, there is evidence of angiogenesis but no evidence of displaying an abnormal 
lymphatic drainage [69]. The long-circulating delivery vehicles have been evidenced 
to specifically accumulate within the pannus of the inflamed synovium [70]. The 
hyperplasia in pannus exhibits a leaky vasculature due to high vascular permeability 
comparable to solid tumors. Consequently, taking advantage of leaky vasculature may 
for passive targeting is a promising option [71]. EPR allows NPs in size range from 20 
to 200 nm to selectively accumulate in pannus and display on the surface of inflamed 
tissue. In addition to the EPR effect, hypoxic and acidic environment of inflamed joint 
also favors passive targeting [70]. Arthritic inflamed joint has poor oxygen delivery 
and increased metabolic rate due to meager perfusion into the diseased synovial joint. 
Therefore, the two conditions can easily be used as method of passive drug target-
ing in less oxygen and acidic microenvironment of RA affected inflamed tissue. NPs 
administrated in blood stream with hydrophobic surface are easily recognized by 
reticuloendothelial system (RES) such as spleen and liver, and engulfed by macro-
phages, consequently quickly eliminated from systemic circulation.
4.2 Active targeting
Targeted delivery involves active targeting to specific cells in the microenvi-
ronment of arthritic joints. Overexpressed receptors on particular immune cells 
can be targeted with its complimentary ligand that is decorated on nanoparticle 
surface. Several receptors are expressed by different cells, we shall be discussing 
a few including CD44, folate and beta-3 integrins. Targeting angiogenic vascular 
endothelial cells are also under investigation, with E-selectin as a promising target 
molecule [72]. Receptor mediated endocytosis is responsible for efficient uptake of 
the ligand decorated carrier molecule (ligand-receptor interaction) (Figure 3).
4.2.1 Folic acid (FA) based active targeting
Activated macrophages overexpress folate receptor β(FR-β) in the arthritic joints 
[73]. Owing to post-translational modifications, the folate expressed on neutrophils 
Figure 3. 
Outline of the targeting strategies for nanoparticulate drug delivery systems used in RA.
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are incapable of binding to FR-β [74]. Alternatively, a functional FR-β has been 
identified on the activated macrophages having nanomolar affinity for folate. 
Hence, the FR-β receptor emerges as a useful target in various diseases including 
RA, osteoarthritis [75], systemic lupus erythematosus [76], atherosclerosis [77] and 
Crohn’s disease [78]. Macrophages are key players of RA pathogenesis, as they secrete 
pro-inflammatory cytokines, metalloproteinases, ROS and prostaglandins. Folate is 
an attractive option for ease of surface modification, hydrophilicity, and stability in 
different solvents. Methotrexate (MTX) encapsulated folate-conjugated glycol chi-
tosan (MFGCN) have been targeted to inflamed joint in adjuvant-induced arthritic 
rat model [79]. Likewise, surface of MTX-loaded liposomes was decorated with 
folate and were evaluated both in vitro and in vivo (DBA/1 J mice strain) [80, 81], 
and targeted against the FR-β on activated macrophages. Clinical efficacy of MTX 
in the DBA/1 J arthritic mice indicated significant expression of CD73. Since, low 
doses were required, this nanoformulation was economical and cost-effective. MTX 
loaded dendrimer nanoparticles with folic acid (FA) surface functionalization were 
reported to reduce progression of disease [82]. Further, authors suggested a ~ 7.5-fold 
increase in the maximum-tolerated dose of the MTX, when given as the formulation 
compared to the free MTX.
4.2.2 Hyaluronic acid (HA) based active targeting
CD44 is a glycoprotein, overexpressed on the surface of activated macrophages, 
present in the inflamed joints of RA. CD44 can be exploited as a prospective target 
in RA treatment. HA, a biocompatible natural polymer has ben explored as a ligand 
that effectively binds to CD44 receptor. HA coated hydroxyapatite NPs (HA-NPs) 
encapsulating methotrexate (MTX) and teriflunomide (TEF) - (HYA-HAMT-NP) 
were reported for RA treatment [83]. Results suggested that HYA-HAMT-NP could 
emerge as an effective delivery vehicle to circumvent hepatotoxicity caused by 
drugs in RA.
4.2.3 Anti-angiogenesis
Hypoxia in a critical factor in inflamed synovium that triggers neo-vascular-
ization from existing vessels termed as angiogenesis [84]. The neo-vascularization 
preserves the chronic inflammatory state by engaging cells to the inflammatory site, 
provides nutrition and oxygen to the multiplying cells. Additionally, the enlarged 
surface of endothelium triggers secretion of adhesion molecules, cytokines and 
stimulates neutrophil infiltration as well as synovial membrane into the cartilage, 
causing cartilage destruction and bone erosion [85]. Promising therapies based 
on angiogenesis are emerging for RA therapy, where VEGF and integrins are the 
therapeutic targets.
4.2.3.1 Vascular endothelial growth factor (VEGF)
Vascular endothelial growth factor (VEGF) is an endothelial-cell-specific 
angiogenic factor principally secreted by SFs in the pannus. In angiogenesis, VEGF 
triggers multiplication and migration of endothelial cells. Further, it enhanced 
blood vascular permeability, stimulates maturation and maintenance of the neo-
vessels [86]. TNF-α and IL-1, the pro-inflammatory cytokines induce the SFs and 
other cells to secrete VEGF, and VEGF is overexpressed at the inflamed joint owing 
to angiogenesis [87]. Therefore, VEGF and VEGF receptor inhibition can be an 




4.2.3.2 Vasoactive intestinal peptide (VIP)
Vasoactive intestinal peptide (VIP) is a neuropeptide of the central and periph-
eral nervous system that has vasodilatory, anti-proliferative, anti-inflammatory, cell 
protective agent and broncho-dilatory role. The activity of VIP binds to high affinity 
VIP receptors, that are overexpressed on T-lymphocytes and several inflammatory 
cells. VIP inhibits the secretion of pro-inflammatory cytokines to act as anti-inflam-
matory molecule. It also promotes the secretion of anti-inflammatory molecules by 
stimulated innate cells [88]. Proliferating synoviocytes and activated macrophages 
overexpress VIP receptors in inflamed RA. Therefore, VIP receptor specific ligands 
can be conjugates to nanoparticles to specifically target the diseased site. Therefore, 
VIP can be exploited as a therapeutic agent for active targeting to RA joint.
4.2.3.3 Integrins
Integrins are the biogenic markers of endothelium undergoing angiogenesis and 
play a vital effector role in it. Integrin alpha-V-beta 3 (αvβ3 integrin), also referred 
to as vitronectin receptor are overexpressed on osteoclasts and activated macro-
phages of the inflamed synovium. Integrin receptor promotes angiogenesis, helps in 
osteoclast-mediated bone resorption, and induces pathological neo-vascularization 
[89]. Inhibition of αvβ3 integrin activity stimulates endothelial cell apoptosis, 
thereby inhibiting angiogenesis [90]. Hence, αvβ3 is considered a reliable maker for 
targeted delivery to RA patients.
4.2.3.4 E-selectin
E- Selectin is a glycoprotein that is associated with leukocyte rolling and adhesion 
and is expressed on vascular endothelium of the inflamed synovium, and promotes 
angiogenesis [91]. The inflammatory cytokines maintain its upregulated expression 
in the inflamed tissue. Therefore, expression of e-selectin can be a useful molecular 
target for RA therapy. Therefore, e-selectin serves as yet another attractive strategy 
for active targeting of the chosen delivery of drug to the diseased RA joint [92].
5. Nanotherapeutics
The assembly of stimuli-sensitive nanoparticles necessities the usage of biocom-
patible constituents, that can undergo supra-molecular changes in conformation, 
a hydrolytic cleavage, and precise protonation, etc. Polymers have maximum 
suitability and has been widely explored class of materials that have incredible 
potential. Polymers may be of natural or synthetic origin. The flexibility of the 
polymer sources and its ability for synthesis of various combinations of polymers 
has facilitated manipulation of the polymer sensitivity to specific stimuli within a 
narrow range [93]. Nanoparticles could be synthesized by lipid, metals and poly-
mers. NPs decoy pro-inflammatory molecules like cytokines and ROS and some-
times osteoclast differentiation factors. Moreover, surface modification of NPs with 
target moiety is a extensive application in site specific drug delivery by enhancing 
the bioavailability of drug and reducing non-target side effects [94].
5.1 Polymer-drug conjugate (PDC)
PDC based DDS has been proposed by Ringsdrof in 1975 [95], in which a low 
molecular weight drug, targeting moiety and solubilizer are attached to polymeric 
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backbone covalently via bioresponsive linkers. PDC improves drug bioavailability, 
reduces drug toxicity, and are less toxic in nature, can easily be fabricated in regulated 
sizes that escape through renal filtration, exhibit increased retention time in blood cir-
culation [96]. PDCs under investigation include N-(2-hydroxypropyl) methacrylamide, 
poly(vinylpyrrolidone) (PVP), hyaluronic acid (HA) and poly (ethylene glycol) (PEG) 
[11, 97]. N-(2-hydroxypropyl) methacrylamide (HPMA) shows improved biodegrad-
ability, biocompatibility and increased efficacy in treating RA [11, 97]. HPMA-Dex 
conjugates were administered intravenously into CIA induced RA model, that resulted 
in accumulation at the inflamed joints [98]. PEG has been used for its hydrophilicity 
and biocompatible properties. PEG-DEX have been developed via acid-labile hydra-
zine bond and given to arthritic rats leading to decrease in joint inflammation [99]. 
Recently, FDA approved two PEGylated proteins for the treatment of RA: Pegloticase 
(Krystexxa®) and certolizumab pegol (CIMZIA®). Although, PEG attributes stealth 
properties to the NPs, there are some concerns regarding PEG conjugates that include 
low biodegradability and the  possibility to elicit an anti-PEG IgM antibody [100].
5.2 Nanoparticles
Nanoparticles are solid colloidal particles with unique physico-chemical proper-
ties such as ultra-small size, surface charge, large surface area to mass ratio Unlike 
polymer-drug conjugates, NPs allow encapsulation/absorption/entrapment of drug 
without modification. The high reactivity, diffusivity, solubility, toxicity, immu-
nogenicity and drug release characteristics can be manipulated to make efficient 
delivery system. Polymeric, liposomes, micelles and metallic nanoparticles are the 
most commonly used nanoparticles [101].
5.2.1 Biopolymeric nanoparticles
The biodegradable backbone in biopolymeric NPs protects the drug from in vitro 
and in vivo degradation. Alginate, Gelatin, Pectin, Chitosan, are natural biopolymers 
that are highly investigated as they are biocompatible and biodegradable. Chitosan is 
polycationic in nature, that allows surface modification with ease and is a natural muco-
adhesive. Kumar et al. reported Chitosan nanoparticles encapsulating Dexamethasone 
(DEX) and Methotrexate (MTX) for their in vitro efficacy in RAW264.7 cells and in vivo 
efficacy in arthritic rat model. Results convincingly indicated reduced toxicity and high 
efficacy in arthritic model [28]. The main drawback of chitosan is insoluble in alkaline 
and neutral medium due to absence of free amino group, but due to protonation of free 
amino group in acidic medium, there is enhanced solubility.
Glycol chitosan has enhanced water solubility and functional groups for further 
chemical modifications making it better suited as a potent drug carrier [102] Glycol-
chitosan nanoparticles(GCNPs) are biocompatible, pH responsive and biodegrad-
able. Methotrexate (MTX) encapsulated folate-conjugated glycol chitosan (MFGCN) 
have been reported to target the overexpressed folate receptors β (FR-β) on activated 
macrophages in the inflamed joint in adjuvant-induced arthritic rat model. Figure 4 
gives a pictorial description of MFGCN that reduced the arthritic index, improved 
the antioxidant response and decreases pro-inflammatory cytokines and suggesting 
its potential in targeting activated macrophages of synovium [79].
5.2.2 Gold nanoparticles(GNPs)
GNPs can be surface functionalized through covalent bonding, by cationic 
polymers or physical or ionic absorption [103], functional groups like e.g. thiol, 
amine, and carboxyl groups that are reactive [104]. GNPs were strategically planted 
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in macrophages to target thioredoxin reductase to evaluate its antiangiogenic impact 
by binding to the vascular endothelial growth factor (VEGF) [105]. Lee et al. sug-
gested MTX encapsulated RGD-attached gold half-shell NP system for RA treat-
ment [106]. On irradiation with near-infrared (NIR), these GNPs delivered MTX 
to the inflamed joints, maximizing its efficacy with minimal side effects. GNPs 
were modified physically with Tocilizumab(TCZ) and chemically altered with an 
end-group thiolated hyaluronate(HA). This complex of HA-GNP-TCZ indicated 
a synergistic effect for its dual-functional effect on VEGF and IL-6R (receptors 
for IL-6) in RA treatment [107]. GNPs may block the RANKL induced osteoclast 
formation which leads to cartilage and bone destruction [108].
5.2.3 Liposomes
Liposomes are bilayered lipids with an aqueous core. Both hydrophobic as well 
as hydrophilic drugs can be encapsulated within phospholipids and the water phase 
cavity, making them SDDS [109]. Particle size determines the extent of accumula-
tion at the synovium, with maximum accumulation of liposomes reported with size 
<100 nm diameter [110]. Therapeutic efficacy is limited due to rapid clearance from 
circulation via the RES in the liver/spleen. Surface modification by PEG enhances 
its hydrophilicity, makes them sterically stabilized, circumvent rapid clearance, 
and enhance the retention time in blood circulation [110]. Corvo et al. reported 
enhanced circulation and accumulation of PEG-coated SOD entrapped liposomes 
(mean diameter ~ 0.11 μm) at the arthritic joints [111]. Considering the dynamic 
microenvironment of the diseased synovium, liposomal surface can be modi-
fied with ligands, antibodies/antibody fragments or for site-specific delivery of 
encapsulated cargo. Recently, dexamethasone encapsulated PEG-liposome treated 
arthritic rats indicated accumulation of liposomes, down regulation of pro-inflam-
matory cytokines along with reduced inflammation of the arthritic joints [112]. 
Liposome tagged with a peptide sequence (CKPFDRALC-called ART-2 ligand) 
encapsulating DEX significantly inhibited RA progression [113].
Figure 4. 
Pictorial representation of utilization of folate functionalized methotrexate loaded glycol chitosan 
nanoparticles (MFGCN) in treating CIA rats targeting inflammation and ROS in rat serum post 21 days of 
treatment (n = 6). [A] MFGCN development and active targeting of M1 macrophages in the inflammatory 
synovium. [B] LPO and LDH activity [C] panel showing antioxidant potential (activity quantification of 
GST, GSH, GP and GR) [D] quantification of TNF-α, IL-4, IL-1β, IL-10 and IL-17 [E] Representative 
H&E staining images of study groups comparing healthy and arthritic control groups with the treatment 
groups(n = 6). Data was analyzed by one-way ANOVA *p < 0.05, **p < 0.01, ***p < 0.001.
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5.2.4 Micelles
Micelles can be synthesized in small size with narrow size distribution from 
amphiphilic molecules that self-assemble into NPs in aqueous solution with a 
distinct hydrophobic cavity and an exterior hydrophilic surface. This makes them 
apt for intravenous injection and targeted delivery into the inflamed synovium 
as a consequence of extravasation through leaky vasculature and subsequent 
inflammatory cell-mediated sequestration (ELVIS) [114]. Wang et al. reported 
self-assembled micelles with an amphiphilic copolymer PEG-poly-e-caprolactone 
(PEG-PCL), which displayed ELVIS in inflamed joints [115], but the non-
biodegradable backbone of synthetic polymers caused non-specific accumulation 
in liver. Bader et al. [116] developed micelles from polysialic acid (PSA)-the 
hydrophilic polymer and synthesized micelles by altering it with N-decylamine 
(DA) and PCL, that formed the hydrophobic fragment. Prolonged circulation was 
observed with these micelles that accumulated passively at the inflamed tissue. 
PSA-DA micelles exhibited in-vitro cytotoxicity towards a synovial fibroblast cell 
line, the PSA-PCL micelles displayed negligible in-vivo cytotoxicity [117]. Further 
modifications were reported to improve the blood kinetic profile of the micelles. 
Core-cross-linked micelles were developed based on copolymer PEG-b-poly 
[N-(2-hydroxypropyl) methacrylamide-lactate] for targeted delivery of glucocor-
ticoids to the RA affected joints. Here, dexamethasone was modified by methac-
rylated linkers via ester bonds, and covalently encapsulated within the polymeric 
structure, leading to tailorable release of dexamethasone [118]. Targeted delivery 
of aqueous-synthesized MTX-PEI@HA NPs to mitigate inflammatory arthritis 
was reported [114]. Li et al. formulated pH-sensitive micelles by conjugating 
hydrophobic prednisolone to PEG-derivative that confers acid-sensitive sites for 
attachment by forming hydrazone bonds [119]. Dual-drug loading of nimesulide 
and MTX in RGD-modified micelles to target αvβ3-integrin validated efficient 
site-specific delivery, decreased angiogenesis with minimal dose of nimesulide 
and MTX [120].
6. Conclusion
Multifactorial pathogenesis is the hallmark in RA causing bone fragility and 
functional erosion linked disability in extreme conditions. Although, conventional 
therapeutic formulations alone or in combination may relieve the symptoms, these 
are associated with complex adverse reactions. Dose-escalation, immunogenic-
ity, systemic toxicity, and non-specific biodistribution in tissues warrant SDDS 
development. Stimuli-responsive NPs target specific inflammatory intermediaries, 
thereby suppressing the pathophysiological cascade, that may alleviate RA symp-
toms and delay joint destruction. Therefore, both the approaches may be exploited 
for achieving dose reduction coupled with drug accumulation at the targeted 
inflamed joint.
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